CohBar (OTC: CWBR) researches and develops of mitochondria-based therapeutics (MBTs), an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This discovery was made by CohBar founders, pioneers in the biology of aging, metabolism and mitochondrial genomics. MBTs offer the potential to address a broad range of diseases such as Type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders. For more information, visit the company’s website at www.cohbar.com